Menu
Back to Journals » Clinical Interventions in Aging » Volume 8
The influence of selective vitamin D receptor activator paricalcitol on cardiovascular system and cardiorenal protection
Authors Duplancic D, Cesarik M, Poljak N, Radman M, Kovacic V, Radic J, Rogosic V
Received 20 September 2012
Accepted for publication 2 November 2012
Published 11 February 2013 Volume 2013:8 Pages 149—156
DOI https://doi.org/10.2147/CIA.S38349
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Darko Duplancic,1 Marijan Cesarik,2 Nikola Kolja Poljak,3 Maja Radman,4 Vedran Kovacic,5 Josipa Radic,5 Veljko Rogosic6
1Department of Cardiology, School of Medicine in Split, University Hospital Split, Split, Croatia; 2Department for Neurology, County General Hospital Pozega, Pozega, Croatia; 3Department of Otorhinolaryngology, 4Department of Endocrinology, 5Department of Nephrology, 6Department of Ophthalmology, School of Medicine in Split, University Hospital Split, Split, Croatia
Abstract: The ubiquitous distribution of vitamin D receptors in the human body is responsible for the pleiotropic effects of vitamin D-receptor activation. We discuss the possible beneficial effects of a selective activator of vitamin D receptor, paricalcitol, on the cardiovascular system in chronic heart failure patients and chronic kidney patients, in light of new trials. Paricalcitol should provide additional clinical benefits over the standard treatment for chronic kidney and heart failure, especially in cases of cardiorenal syndrome.
Keywords: vitamin D deficiency, cardiovascular system, albuminuria, inflammation
© 2013 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.